InvestSMART

Nexsen Limited (ASX: NXN) - Share Price

- Current share price for NXN : $0.160

Nexsen Limited (NXN) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a nano-biotechnology company developing lab-quality diagnostics and sensors that deliver results in minutes - no lab, no delays. The company's modular platform combines advanced materials, biomarker discovery, and machine learning to create scalable, user-friendly tests with unmatched sensitivity and simplicity.

NXN General Information +

ASX Code NXN
Website http://www.nexsen.bio
Industry/Sector Biotechnology
Market Cap ($M) 14
NXN Share Price $0.160
Day High $0.165
Day Low $0.160
Last Close $0.160
NXN Share Price Movement - ( No change )
Prices as at 16:40, 3 Nov 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Nexsen Limited (NXN) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Nexsen Limited (NXN) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Nexsen Limited (NXN) price-sensitive announcements

NXN - ISO 13485 Certification brings StrepSure closer to market
Nexsen Limited announced that it has achieved ISO 13485:2016 certification for the quality
Nexsen Limited (NXN)
2 Nov 2026 | 9:20 AM
NXN - Quarterly Report - Q1 FY27
Nexsen Limited’s Quarterly Report for Q1 FY27, being the quarter ended 30 September 2026 u
Nexsen Limited (NXN)
28 Oct 2026 | 8:20 AM
NXN - Reinstatement to Quotation
ASX announced that the suspension of trading in Nexsen Limited’s securities would be lifte
Nexsen Limited (NXN)
25 Sep 2026 | 9:40 AM
NXN - Proposed FlashDx joint venture builds on CE-marked GBS test
Nexsen Limited (ASX:NXN) announced a non-binding term sheet with FlashDx Shenzhen Inc. to
Nexsen Limited (NXN)
25 Sep 2026 | 9:40 AM

Nexsen Limited (NXN) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Nexsen Limited (NXN)
ORDINARY FULLY PAID
 Health Care $15 Co Secretary Appoint/Resign and Change of Registered Address 2 Nov 2026 5:12PM $0.160 $0.160 fallen by 0%
Nexsen Limited (NXN)
ORDINARY FULLY PAID
 Health Care $15 ISO 13485 Certification brings StrepSure closer to market 2 Nov 2026 9:20AM $0.160 $0.160 fallen by 0%
Nexsen Limited (NXN)
ORDINARY FULLY PAID
 Health Care $15 Quarterly Report - Q1 FY27 28 Oct 2026 8:20AM $0.165 $0.160 fallen by 3.03%
Nexsen Limited (NXN)
ORDINARY FULLY PAID
 Health Care $15 Notice of AGM and Meeting Materials 7 Oct 2026 5:39PM $0.130 $0.160 risen by 23.08%
Nexsen Limited (NXN)
ORDINARY FULLY PAID
 Health Care $15 Professor Shekhar Kumta appointed Executive Director 1 Oct 2026 8:14AM $0.125 $0.160 risen by 28%
Nexsen Limited (NXN)
ORDINARY FULLY PAID
 Health Care $15 Reinstatement to Quotation 25 Sep 2026 9:40AM $0.165 $0.160 fallen by 3.03%

NXN Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$6.29 -$3.50 39.00% 0.00 0.00 0.00% 0.0%
2025A -$5.02 -$2.50 0.00% 0.00 0.00 0.00% 0.0%
2024A $0.00 N2 0.00% 0.00 0.00 0.00% 0.0%

NXN Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
CSL Limited (CSL) $96,534M 0.7309 -0.4395 0.0602 12.4623 22.2350 20.9730 2.11% 2.12% 2.19%
Mesoblast Limited (MSB) $2,811M -0.4501 0.0000 0.0000 0.0000 0.0000 981.8182 0.00% 0.00% 0.00%
Nexsen Limited (NXN) $15M 0.3904 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
PYC Therapeutics Limited (PYC) $1,871M -0.3971 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $4,452M -1.3893 0.0000 -0.5230 0.0000 154.0636 322.9630 0.00% 0.00% 0.00%

NXN Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 5.65 0.00
Market 0.30 13.10 1.02 0.74
Sector 0.76 34.60 2.26 2.03

NXN Directors

Name Position Start Date
Professor Shekhar Kumta Executive Director 3 Dec 2025
Mr Mark Anthony Muzzin Managing Director 1 Jan 0001
Mr Reece O'Connel Non-Executive Chairman, Non-Executive Director 9 Jun 2025
Mr Grant Anthony Pestell Non-Executive Director 1 Jan 0001
Dr Martina Mariano Non-Executive Director 1 Jan 0001

Nexsen Limited (NXN) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value

See all changes in directors' interest & trades for Nexsen Limited (NXN) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

NXN Management

Name Position
Richard Jarvis Chief Financial Officer
Vipul Bansal Chief Innovation Officer and Other Corporate Officer
Sanje Mahasivam Chief Technology Officer
Sonny Didugu Company Secretary

NXN Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Nexsen Limited (NXN). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
37,000,000 (18.48%) Mark Muzzin
14,050,000 (7.02%) Regal Funds Management Pty Ltd and its associates
12,000,000 (5.99%) Ajava Holdings Pty Ltd

NXN Calendar of Events

Date Event
30 August 2027 Report (Annual)
30 August 2027 Report (Prelim)
26 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.